Found 5 results
Filters: Keyword is Double-Blind Method  [Clear All Filters]
2022
Longbrake EE, Hua LH, Mowry EM, Gauthier SA, Alvarez E, Cross AH, Pei J, Priest J, Raposo C, Hafler DA et al..  2022.  The CELLO trial: Protocol of a planned phase 4 study to assess the efficacy of Ocrelizumab in patients with radiologically isolated syndrome.. Mult Scler Relat Disord. 68:104143.
2019
Merkies ISJ, van Schaik IN, Léger J-M, Bril V, van Geloven N, Hartung H-P, Lewis RA, Sobue G, Lawo J-P, Durn BL et al..  2019.  Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies.. J Peripher Nerv Syst. 24(1):48-55.
2018
Fox RJ, Coffey CS, Conwit R, Cudkowicz ME, Gleason T, Goodman A, Klawiter EC, Matsuda K, McGovern M, Naismith RT et al..  2018.  Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis.. N Engl J Med. 379(9):846-855.
2017
Murthy SB, Awad I, Harnof S, Aldrich F, Harrigan M, Jallo J, Caron J-L, Huang J, Camarata P, Lara LRivera et al..  2017.  Permanent CSF shunting after intraventricular hemorrhage in the CLEAR III trial.. Neurology. 89(4):355-362.
2016
Fox RJ, Coffey CS, Cudkowicz ME, Gleason T, Goodman A, Klawiter EC, Matsuda K, McGovern M, Conwit R, Naismith R et al..  2016.  Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis.. Contemp Clin Trials. 50:166-77.